报价延迟最少15分钟:2026/03/02 22:54 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
314.36 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
0.52/11.16
|
|
企业价值
35.26B
|
| 资产负债 |
|
每股账面净值
37.32
|
| 现金流量 |
|
现金流量率
0.02
|
| 损益表 |
|
收益
238.39M
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton'styrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products. |
